Nothing Special   »   [go: up one dir, main page]

DE60135674D1 - Nateglinid enthaltende präparate - Google Patents

Nateglinid enthaltende präparate

Info

Publication number
DE60135674D1
DE60135674D1 DE60135674T DE60135674T DE60135674D1 DE 60135674 D1 DE60135674 D1 DE 60135674D1 DE 60135674 T DE60135674 T DE 60135674T DE 60135674 T DE60135674 T DE 60135674T DE 60135674 D1 DE60135674 D1 DE 60135674D1
Authority
DE
Germany
Prior art keywords
nateglinid
containing preparations
nateglinide
antidiabetic
immediate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60135674T
Other languages
English (en)
Inventor
N Ninomiya
Chisato Makino
Akira Yabuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Application granted granted Critical
Publication of DE60135674D1 publication Critical patent/DE60135674D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60135674T 2000-10-24 2001-10-23 Nateglinid enthaltende präparate Expired - Lifetime DE60135674D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000324373 2000-10-24
PCT/JP2001/009291 WO2002034254A1 (fr) 2000-10-24 2001-10-23 Preparations contenant du nateglinide

Publications (1)

Publication Number Publication Date
DE60135674D1 true DE60135674D1 (de) 2008-10-16

Family

ID=18801918

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60135674T Expired - Lifetime DE60135674D1 (de) 2000-10-24 2001-10-23 Nateglinid enthaltende präparate

Country Status (17)

Country Link
US (2) US7605180B2 (de)
EP (1) EP1334720B1 (de)
JP (3) JP4501054B2 (de)
KR (1) KR100869039B1 (de)
CN (1) CN100352432C (de)
AT (1) ATE406885T1 (de)
AU (1) AU2001295999A1 (de)
BR (1) BR0114896A (de)
CA (1) CA2426263C (de)
DE (1) DE60135674D1 (de)
DK (1) DK1334720T3 (de)
ES (1) ES2307653T3 (de)
MX (1) MXPA03003685A (de)
PT (1) PT1334720E (de)
RU (1) RU2271805C2 (de)
TW (1) TWI283573B (de)
WO (1) WO2002034254A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022294A3 (cs) * 1999-12-28 2002-11-13 Ajinomoto Co., Inc. Antidiabetický preparát k orálnímu uľití
AU2001241168B2 (en) * 2000-03-17 2005-06-16 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
JP4114200B2 (ja) * 2000-10-18 2008-07-09 味の素株式会社 ナテグリニド結晶の製造方法
RU2287520C2 (ru) * 2000-10-18 2006-11-20 Адзиномото Ко., Инк. Способ получения ацилфенилаланинов
SI1334721T1 (sl) * 2000-10-24 2009-08-31 Ajinomoto Kk Hidrofilni farmacevtski pripravki, ki vsebujejo nateglinid
RU2275354C2 (ru) * 2000-10-24 2006-04-27 Адзиномото Ко., Инк. Способы получения кристаллов в-типа натеглинида
JP4501054B2 (ja) * 2000-10-24 2010-07-14 味の素株式会社 ナテグリニド含有製剤
JP4833464B2 (ja) * 2001-11-28 2011-12-07 大正製薬株式会社 難溶性薬物含有固形製剤の製造方法
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7420084B2 (en) 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
WO2005020979A1 (en) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited A process for the preparation of pharmaceutical compositions of nateglinide
US20070219250A1 (en) * 2003-11-28 2007-09-20 Romi Singh Pharmaceutical Compositions of Nateglinide
JP5168712B2 (ja) * 2004-04-01 2013-03-27 味の素株式会社 ナテグリニド含有製剤
JP5551852B2 (ja) * 2004-08-10 2014-07-16 味の素株式会社 苦味の低減したナテグリニド含有製剤
EP1891971A4 (de) * 2005-01-31 2010-02-03 Ajinomoto Kk Medizinische zusammensetzung mit hyperglykämiemittel zur linderung oder behandlung von glucose-intoleranz, borderline-diabetes, insulinresistenz und hyperinsulinämie
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
SG179497A1 (en) 2007-03-29 2012-04-27 Daiichi Sankyo Co Ltd Pharmaceutical composition
TR200801178A2 (tr) * 2008-02-22 2009-09-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Nateglinid ve surfaktan-ph ayarlayıcı sistemi içeren oral tablet kompozisyonları
CN101590063A (zh) * 2008-05-26 2009-12-02 中国科学院上海生命科学研究院 丹参酮iia在制备治疗肥胖及胰岛素抵抗的药物中的应用
KR101792299B1 (ko) 2010-03-19 2017-10-31 다이이찌 산쿄 가부시키가이샤 항응고제의 용출 개선 방법
KR20130087485A (ko) 2010-06-14 2013-08-06 씨아이피엘에이 엘티디. 나테글리니드의 제조 방법
ES2673182T3 (es) 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
CN102813636B (zh) * 2012-08-28 2014-04-16 西南药业股份有限公司 那格列奈片及其制备方法
MX370853B (es) * 2013-07-22 2020-01-08 Sandoz Ag Formulaciones que contienen dapagliflozina amorfa.
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
JP6647902B2 (ja) * 2015-10-30 2020-02-14 株式会社ファンケル 徐放性顆粒剤
KR20240025990A (ko) * 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110612A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
JPH0249720A (ja) * 1988-05-18 1990-02-20 Mitsubishi Kasei Corp 難溶性薬剤組成物
US5041232A (en) * 1990-03-16 1991-08-20 Lever Brothers Company, Division Of Conopco, Inc. Sulfonimines as bleach catalysts
JPH0415221A (ja) 1990-05-08 1992-01-20 Daicel Chem Ind Ltd ポリカーボネートの製造法
DE10199058I2 (de) * 1991-07-30 2006-04-27 Alcm Co Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
EP1586314B1 (de) * 1996-11-15 2011-03-30 Ajinomoto Co., Inc. Nateglinide-Tablettenzubereitungen
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
KR100610403B1 (ko) * 1998-01-20 2006-08-10 어플라이드 애널리티컬 인더스트리즈, 인크. 경구용 액상 또는 반-고체 조성물을 포함하는 약제학적 조성물 및 이의 제조방법
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CZ20022294A3 (cs) * 1999-12-28 2002-11-13 Ajinomoto Co., Inc. Antidiabetický preparát k orálnímu uľití
AU2001241168B2 (en) * 2000-03-17 2005-06-16 Ajinomoto Co., Inc. Drugs for complications of diabetes and neuropathy and utilization thereof
JP4114200B2 (ja) * 2000-10-18 2008-07-09 味の素株式会社 ナテグリニド結晶の製造方法
RU2287520C2 (ru) * 2000-10-18 2006-11-20 Адзиномото Ко., Инк. Способ получения ацилфенилаланинов
SI1334721T1 (sl) * 2000-10-24 2009-08-31 Ajinomoto Kk Hidrofilni farmacevtski pripravki, ki vsebujejo nateglinid
JP4501054B2 (ja) * 2000-10-24 2010-07-14 味の素株式会社 ナテグリニド含有製剤
RU2275354C2 (ru) * 2000-10-24 2006-04-27 Адзиномото Ко., Инк. Способы получения кристаллов в-типа натеглинида
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤

Also Published As

Publication number Publication date
TWI283573B (en) 2007-07-11
CN1482903A (zh) 2004-03-17
DK1334720T3 (da) 2009-01-19
CA2426263C (en) 2010-05-25
JP2010100654A (ja) 2010-05-06
BR0114896A (pt) 2003-08-12
RU2271805C2 (ru) 2006-03-20
MXPA03003685A (es) 2004-01-26
CN100352432C (zh) 2007-12-05
EP1334720A1 (de) 2003-08-13
JP5610165B2 (ja) 2014-10-22
ES2307653T3 (es) 2008-12-01
US7605180B2 (en) 2009-10-20
US20040014815A1 (en) 2004-01-22
PT1334720E (pt) 2008-09-30
WO2002034254A1 (fr) 2002-05-02
JPWO2002034254A1 (ja) 2004-08-26
KR20030042027A (ko) 2003-05-27
EP1334720B1 (de) 2008-09-03
JP2013028636A (ja) 2013-02-07
KR100869039B1 (ko) 2008-11-17
JP4501054B2 (ja) 2010-07-14
ATE406885T1 (de) 2008-09-15
AU2001295999A1 (en) 2002-05-06
EP1334720A4 (de) 2004-02-04
CA2426263A1 (en) 2003-04-23
US20090203791A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
ATE406885T1 (de) Nateglinid enthaltende präparate
NZ527032A (en) Isoxazoline derivative and herbicide containing the same as the active ingredient
NO20016107L (no) Mesalazin-kontrollert frigivelse orale farmasöytiske sammensetninger
HUP0101237A1 (hu) Elnyújtott kioldódású gyógyszerkészítmények
NO20026037L (no) Sötvareprodukt som inneholder aktive bestanddeler
DK1300398T3 (da) Propan-1,3-dionderivat
DE60210784D1 (de) Orale antidiabetische wirkstoffe
DK1330458T3 (da) N-(1,2,4-triazoloazinyl)thiophensulfonamidforbindelser som herbicider
DK1389213T3 (da) 3,7-Diazabicyclo[3.3.1]formuleringer som antiarytmiske forbindelser
WO2003024933A1 (fr) Derive d'acide 2-phenyle-3-heteroarylpropionique ou son sel et medicaments le contenant
ITMI20000440A0 (it) Forme solide orali a rilascio controllato contenenti mesalazina come principio attivo
USD456051S1 (en) Exercise device
EP1462112A4 (de) Mittel zur behandlung von augentrockenheit und damit zusammenhängenden erkrankungen
ZA200304928B (en) Medicament containing a polyamine as an active substance.
EP1026162A4 (de) Antirheumatika
ATE365734T1 (de) Herbizide furanyl- und thienyloxyazine
NO913019D0 (no) Faste orale preparatformer som inneholder ifosfamid som virksomt stoff.
ITMI20001848A0 (it) Faramaci per l'incontinenza.
NO20034528L (no) 3,7-diazabicyklo(3,3,1) formuleringer som antiarytmiforbindelser
AU1389702A (en) Optically active 2,5-bisaryl-delta<sup>1</sup>-pyrrolines and their use as pest control agents
WO2002024210A3 (en) Halogen compounds for use in medicine
RU2000118409A (ru) Антимутагенное средство
NO20030474D0 (no) Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel
ITMI20000972A0 (it) Formulazioni farmaceutiche, a rilascio modificato, con elevata biodisponibilita', contenenti principi attivi ad attivita' antibiotica.
Fitzerald Guilty until proven innocent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition